TML-6,98.34%

产品编号:Bellancom-137315| CAS NO:1462868-88-7| 分子式:C30H37NO7| 分子量:523.62

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-137315
3500.00 杭州 北京(现货)
Bellancom-137315
5800.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

TML-6

产品介绍 TML-6 是一种口服有效的姜黄素衍生物,抑制 β-淀粉样前体蛋白和 β-淀粉样蛋白 () 的合成。TML-6 上调 Apo E,抑制 NF-κBmTOR,并增加抗氧化 Nrf2 基因的活性。TML-6 具有用于阿尔茨海默氏病 (AD) 研究的潜力。
生物活性

TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research.

体外研究

TML-6 (0.65-5.24 µg/mL; for 24 h) reduces the protein expression levels of APP and phospho-NF-κB, and induces the protein expression level of ApoE. TML-6 inhibits the mTOR signaling pathway through the suppression of phospho-mTOR.
TML-6 (0.31, 0.63, 2.5, 5, 10, 20 μM; 24 h) reveals no cytotoxicity in Huh-7 cells at concentrations below 5 μM and has an IC50 of 4.19 µg/mL (8 μM).
TML-6 (1.05, 2.09, 3.14, 4.19 μg/mL; 24 h) reduces the production of Aβ40 and Aβ42 between 1.05, 2.09 and 3.14 μg/mL (equal to 2, 4 and 6 μM) in a dose-dependent manner in N2a/APPswe cell.
TML-6 can exhibit transcriptional activation of the Nrf2 gene in a dose-dependent manner, with the highest activity at a concentration of 1.32 µg/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line: Huh-7 cells
Concentration: 0.65, 1.31, 1.96, 2.61, 3.93, 5.24 µg/mL
Incubation Time: For 24 hours
Result: Reduced the amyloid precursor protein (APP) protein expression level by 60% and decreased the level of phosphorylated NF-κB by about 50% at a dose of 1.96 µg/mL after 24 h treatment.
Induced the protein expression level of ApoE by approximately 44% at a dose of 2.62 µg/mL.
体内研究
(In Vivo)

TML-6 (diet; 150 mg/kg/day; for four months) treatment results in significant improvement in learning, suppression of the microglial activation marker Iba-1, and reduction in Aβ in the brain.
TML-6 (oral; 150 mg/kg) has a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-month-old 3xTg (mutations: APPKM670/671NL, MAPTP301L and PSEN1M146V) AD transgenic mice
Dosage: 150 mg/kg
Administration: Diet; daily; for four months
Result: Improved the learning behaviors, significantly suppressed the Aβ levels and Iba-1 expression in the brain of 3xTg AD transgenic mice.
Animal Model: SD rats
Dosage: 150 mg/kg (Pharmacokinetic Analysis)
Administration: Oral
Result: Had a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.
体内研究

TML-6 (diet; 150 mg/kg/day; for four months) treatment results in significant improvement in learning, suppression of the microglial activation marker Iba-1, and reduction in Aβ in the brain.
TML-6 (oral; 150 mg/kg) has a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-month-old 3xTg (mutations: APPKM670/671NL, MAPTP301L and PSEN1M146V) AD transgenic mice
Dosage: 150 mg/kg
Administration: Diet; daily; for four months
Result: Improved the learning behaviors, significantly suppressed the Aβ levels and Iba-1 expression in the brain of 3xTg AD transgenic mice.
Animal Model: SD rats
Dosage: 150 mg/kg (Pharmacokinetic Analysis)
Administration: Oral
Result: Had a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.
体内研究

TML-6 (diet; 150 mg/kg/day; for four months) treatment results in significant improvement in learning, suppression of the microglial activation marker Iba-1, and reduction in Aβ in the brain.
TML-6 (oral; 150 mg/kg) has a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-month-old 3xTg (mutations: APPKM670/671NL, MAPTP301L and PSEN1M146V) AD transgenic mice
Dosage: 150 mg/kg
Administration: Diet; daily; for four months
Result: Improved the learning behaviors, significantly suppressed the Aβ levels and Iba-1 expression in the brain of 3xTg AD transgenic mice.
Animal Model: SD rats
Dosage: 150 mg/kg (Pharmacokinetic Analysis)
Administration: Oral
Result: Had a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.
性状Solid
溶解性数据
In Vitro: 

DMSO : 120 mg/mL (229.17 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9098 mL 9.5489 mL 19.0978 mL
5 mM 0.3820 mL 1.9098 mL 3.8196 mL
10 mM 0.1910 mL 0.9549 mL 1.9098 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服